Shamburg News · 8-K filed Nov 5, 2026, 7:15 AM EST
Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Clinical Update
ACRS · Aclaris Therapeutics, Inc.
- Earnings
- Financing
- Materiality: high
Aclaris Therapeutics reported a net loss of $18.5 million for the third quarter of 2026 compared with $14.6 million a year earlier, and total revenue of $1.5 million compared with $3.3 million. Net loss per share was $(0.12) for the quarter, unchanged from the prior-year quarter. The company reported cash, cash equivalents and marketable securities of $204.6 million as of September 30, 2026, and said it sold 7.8 million shares plus pre-funded warrants for $50.0 million gross proceeds in October 2026.
Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001104659-26-123039.
Written from the filing by Shamburg Markets. Figures are as reported by the company.